CymitQuimica logo

2'-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimid in]-6'-one

Ref. 3D-FM160676

ne
Discontinued

Discontinued product. For inquiries about similar products, please fill out our form or email us at .

2'-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazi…
Biosynth

    Product Information

    Name:2'-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimid in]-6'-one
    Synonyms:
    • Trilaciclib
    Brand:Biosynth
    Description:2'-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimid in]-6'-one is a potent inhibitor of CDK4/CDK6 and has been shown to be an effective treatment for cancer. It inhibits the phosphatase activity of these enzymes and prevents the activation of cyclin D. This inhibition leads to cell cycle arrest at the G0/G1 phase. The cytotoxic effects of 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H spiro[cyclohexane 1
    Notice:Our products are intended for lab use only. For any other use, please contact us.

    Chemical properties

    Molecular weight:446.55 g/mol
    Formula:C24H30N8O
    Purity:Min. 95%
    InChI:InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)
    InChI key:InChIKey=PDGKHKMBHVFCMG-UHFFFAOYSA-N
    SMILES:CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1

    Inquiry about discontinued product: 2'-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimid in]-6'-one

    ◻️
    CYMIT QUÍMICA, S.L. as responsible for the treatment will treat your data in order to respond to your queries or requests. You can access, rectify and delete your data, as well as exercise other rights by consulting the additional and detailed information on data protection in our Web Privacy Policy.
    * Mandatory fields.